Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
about
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cellsImpacts of tissue-type plasminogen activator (tPA) on neuronal survivalCombined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic strokeDiverse impact of acute and long-term extracellular proteolytic activity on plasticity of neuronal excitabilityVascular protection to increase the safety of tissue plasminogen activator for strokeActivated protein C: A regulator of human skin epidermal keratinocyte functionOxidative Stress and the Use of Antioxidants in StrokeProtein C anticoagulant and cytoprotective pathwaysCytoprotective-selective activated protein C therapy for ischaemic strokePhosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPAProtein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like regionAncillary approaches to plasminogen activators.Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis.Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impactEthanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors.Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impactMolecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activatorActivated protein C action in inflammationThrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor.Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrierRegulation of the protein C anticoagulant and antiinflammatory pathways.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.The science of stroke: mechanisms in search of treatments.Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus.Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicityProtein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway.IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.Tissue plasminogen activator prevents white matter damage following stroke.Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.Advances in revascularization for acute ischemic stroke treatment.An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury.Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic strokeCytoprotective protein C pathways and implications for stroke and neurological disordersDeleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia
P2860
Q24646845-6A43E29D-D286-4ED3-BD3D-797BC55E531DQ26777261-D7676C53-5A03-45D9-93AD-5D39C8AD42A7Q26782990-97652DD2-6C24-4B55-B97E-B83C817DE58AQ26796239-3D0090C9-E49D-48CF-8B15-E867BA922F96Q26824338-E4461353-815E-4910-B6DA-F8FDD8A10BD7Q26830499-A4703AE2-A1A9-4ACC-80C2-9437E2E8CE78Q26852796-01190C42-F68B-42D5-B5C3-C61FD8417105Q26999113-E78A3B50-85D1-4F74-8511-947CBD973363Q27009122-217AE9F2-0145-4ADB-9249-51C55C9D63DCQ28476434-61C33B3F-8DFB-4DF2-9486-E719635E69D5Q28592005-212D9528-F2F6-484E-A5B0-F1E165A721E3Q31095961-F69CA0FB-FAAD-4E57-87ED-938958EDD8BEQ33369942-CD78F0CA-0B9B-4211-90F2-5FB131D9D529Q33563314-1E36869B-92AB-4111-A808-595125CE3E5FQ33567131-2222D41F-CCA2-4D5B-A3E6-3BBE80608E4DQ33722964-207932E5-68BF-4E2E-9C0D-EFFCD4C6883EQ33749766-BB0FAB71-C5ED-494D-8C62-111A9BDF15E3Q33798916-A6DF03B4-3478-4454-91B0-8B7579C65308Q33823616-CC1243A8-4F2F-4A16-9F11-71D5485162ACQ33846825-16FDF8FA-D986-4ADA-AA0F-3B96364A6193Q33879440-3DAB14BF-885D-49B1-B316-5D9155AD543DQ33931826-27B64CBB-AB6A-4571-B5FA-472668915D3EQ33954036-44C5BE9F-ABD9-43AA-8F56-0A4E5C03A687Q33996371-41160A8F-6F59-4454-8E97-DC4F8EAFA216Q34006140-A31E7C09-E37A-4DEF-96F0-345343A628B8Q34212337-32A81BA0-0B51-4176-A01B-9390A5DCD019Q34212891-96454D3F-7947-4D65-85BA-FDAD0AEFEC9BQ34501341-41279784-A6F1-4935-95F4-19293B5146D4Q34504984-C968AB8C-B666-436C-8776-A6C30CEB97ABQ34589575-A6B50452-A752-4AEA-8F54-7E5C3ED63F47Q35125778-E19EB9C2-E802-4DDD-AD12-070F125FC84DQ35213585-9AA34B18-427C-4F1A-A41A-006A91F5E59AQ35567319-37A2AB4C-5D6D-49A6-BAA1-3C6B394A7983Q35591917-E8677237-E33F-4B43-8460-748549724037Q36106802-A2AA0B8A-581B-4486-A8FE-BDA03AF8A295Q36195195-B89768B2-2DCD-435C-B8FD-9B63C0076AA2Q36259819-859DAD1E-4466-4A75-AA7A-D2AA63B1C256Q36319554-519AD177-F2D8-41FF-8D01-8E87C98663ACQ36379329-152C11D4-13E3-421F-9C38-7F8A997F5749Q36691135-3152D182-1170-4BE9-A895-F148B2675A56
P2860
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@en
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@nl
type
label
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@en
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@nl
prefLabel
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@en
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
@nl
P2093
P2860
P356
P1433
P1476
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C
@en
P2093
Berislav V Zlokovic
José A Fernández
Tong Cheng
Xiaomei Song
P2860
P2888
P304
P356
10.1038/NM1122
P407
P577
2004-10-31T00:00:00Z